FCM
CBAY

Flinton Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Flinton Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$14K Hold
2,686
– – ﹤0.01% 879
2019
Q2 		$19K Hold
2,686
– – ﹤0.01% 862
2019
Q1 		$36K Hold
2,686
– – ﹤0.01% 832
2018
Q4 		$21K Buy
+2,686
New +$25.6K ﹤0.01% 826

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Flinton Capital Management's CBAY Position: Q3 2019 in Review

Flinton Capital Management held its Cymabay Therapeutics (CBAY) position steady in Q3 2019 at 2,686 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #879.

Flinton Capital Management first reported a position in CBAY in Q4 2018 and has held it in 4 quarters since. The position peaked at $36K in Q1 2019. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

  • Flinton Capital Management held 2,686 shares of Cymabay Therapeutics worth $14K as of Q3 2019.
  • Flinton Capital Management left its Cymabay Therapeutics share count unchanged in Q3 2019.
  • Cymabay Therapeutics made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #879 holding.
  • Flinton Capital Management first reported a position in Cymabay Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Flinton Capital Management's Cymabay Therapeutics position peaked at $36K in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.